Celldex Therapeutics Inc

詳細情報 Celldex Therapeutics Inc 企業名

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

Celldex Therapeutics Incの企業情報



企業コードCLDX

会社名Celldex Therapeutics Inc

上場日May 15, 1986

最高経営責任者「CEO」Mr. Anthony S. Marucci

従業員数186

証券種類Ordinary Share

決算期末May 15

本社所在地53 Frontage Road

都市HAMPTON

証券取引所NASDAQ Capital Market Consolidated

国United States of America

郵便番号08827

電話番号19084547120

ウェブサイトhttps://celldex.com/

企業コードCLDX

上場日May 15, 1986

最高経営責任者「CEO」Mr. Anthony S. Marucci

Celldex Therapeutics Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Anthony S. Marucci

President, Chief Executive Officer, Director

40.64K

+1.48%

Mr. Freddy A. Jimenez, Esq., J.D.

Senior Vice President, General Counsel

33.37K

-2.26%

Dr. Diane C. Young, M.D.

Senior Vice President, Chief Medical Officer

17.11K

-63.67%

Dr. Margo Heath-Chiozzi, M.D.

Senior Vice President - Regulatory Affairs

13.74K

+2.70%

Ms. Elizabeth Crowley

Senior Vice President, Chief Product Development Officer

9.07K

--

Dr. Tibor Keler, Ph.D.

Executive Vice President, Chief Scientific Officer

7.36K

--

Mr. Herbert J. (Herb) Conrad

Independent Director

2.56K

--

Mr. James J. (Jim) Marino

Independent Director

2.20K

--

Mr. Keith L. Brownlie, CPA

Independent Director

666.00

--

Ms. Teri L. Lawver

Senior Vice President, Chief Commercial Officer

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Anthony S. Marucci

President, Chief Executive Officer, Director

40.64K

+1.48%

Mr. Freddy A. Jimenez, Esq., J.D.

Senior Vice President, General Counsel

33.37K

-2.26%

Dr. Diane C. Young, M.D.

Senior Vice President, Chief Medical Officer

17.11K

-63.67%

Dr. Margo Heath-Chiozzi, M.D.

Senior Vice President - Regulatory Affairs

13.74K

+2.70%

Ms. Elizabeth Crowley

Senior Vice President, Chief Product Development Officer

9.07K

--

Dr. Tibor Keler, Ph.D.

Executive Vice President, Chief Scientific Officer

7.36K

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sat, Aug 16

株主統計

種類

株主統計

比率

Wellington Management Company, LLP

11.14%

Kynam Capital Management LP

9.19%

BlackRock Institutional Trust Company, N.A.

6.91%

Fidelity Management & Research Company LLC

5.95%

The Vanguard Group, Inc.

5.93%

他の

60.89%

株主統計

比率

Wellington Management Company, LLP

11.14%

Kynam Capital Management LP

9.19%

BlackRock Institutional Trust Company, N.A.

6.91%

Fidelity Management & Research Company LLC

5.95%

The Vanguard Group, Inc.

5.93%

他の

60.89%

種類

株主統計

比率

Investment Advisor

42.58%

Hedge Fund

32.92%

Investment Advisor/Hedge Fund

31.28%

Venture Capital

3.61%

Research Firm

2.78%

Pension Fund

0.39%

Bank and Trust

0.36%

Individual Investor

0.27%

Insurance Company

0.04%

機関投資家保有株



更新時刻: Wed, Oct 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q3

420

73.66M

110.92%

-14.44M

2025Q2

422

75.86M

114.26%

-13.90M

2025Q1

437

75.31M

113.46%

-13.68M

2024Q4

437

75.05M

113.05%

-8.14M

2024Q3

429

73.28M

110.59%

-7.16M

2024Q2

432

71.48M

107.86%

-10.62M

2024Q1

419

71.32M

108.50%

+952.72K

2023Q4

406

62.72M

112.33%

-412.93K

2023Q3

403

52.10M

110.18%

-8.63M

2023Q2

410

51.84M

109.57%

-7.47M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

Wellington Management Company, LLP

5.23M

7.88%

-3.12M

-37.37%

Jun 30, 2025

Kynam Capital Management LP

6.10M

9.19%

-399.27K

-6.14%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.59M

6.91%

-38.52K

-0.83%

Jun 30, 2025

Fidelity Management & Research Company LLC

3.95M

5.95%

+62.97K

+1.62%

Jun 30, 2025

The Vanguard Group, Inc.

3.94M

5.94%

+56.45K

+1.45%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.75M

5.65%

+398.14K

+11.88%

Jun 30, 2025

Commodore Capital LP

3.45M

5.2%

+100.00K

+2.99%

Jun 30, 2025

Bellevue Asset Management AG

3.31M

4.98%

+235.95K

+7.68%

Jun 30, 2025

Point72 Asset Management, L.P.

2.80M

4.22%

+180.55K

+6.89%

Jun 30, 2025

State Street Investment Management (US)

2.41M

3.62%

-400.86K

-14.28%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

詳細情報 Celldex Therapeutics Inc 企業名

Celldex Therapeutics Incの企業情報

Celldex Therapeutics Incの経営陣

収益内訳

株主

機関投資家保有株

株主動向

関連ETF

配当金

株式分割